Core Viewpoint - Betaini (300957.SZ), known as the "first stock in functional skincare," is intensifying its capital market strategy by investing in a new healthcare fund, aiming to diversify its business beyond its core beauty segment [1]. Investment Strategy - On October 13, Betaini announced plans to invest as a limited partner in the Wuxi Jinyu Maowu Medical Health Industry Investment Partnership (referred to as "Jinyu Fund"), with a total fund size of 1 billion CNY, focusing on consumer healthcare, pharmaceuticals, medical devices, and AI drug development [1][4]. - Betaini will contribute 50 million CNY, acquiring a 5% stake in the Jinyu Fund, which is part of a broader strategy to deepen cooperation with professional funds and enhance its presence in the health ecosystem [4]. Historical Investments - Over the past three years, Betaini has invested approximately 280 million CNY in various funds, including the Sequoia Fund and the San Zheng Fund, indicating a strategic shift towards capital investments to seek growth opportunities [3][9]. - The company has made several notable investments: 100 million CNY in the Sequoia Fund in June 2022, another 100 million CNY in the San Zheng Fund in April 2023, and 30 million CNY in the Jinguo Fund in October 2023 [5][9]. Financial Performance - Betaini's revenue growth has been declining, with reported revenues of 4.022 billion CNY in 2021, 5.014 billion CNY in 2022, 5.522 billion CNY in 2023, and 5.736 billion CNY in 2024, showing a decreasing growth rate from 52.57% to 3.87% [9]. - The net profit has also seen a downward trend, with figures of 863 million CNY in 2021, 1.051 billion CNY in 2022, 757 million CNY in 2023, and 503 million CNY in 2024, reflecting a significant decline in profitability [9]. Market Position and Competition - Betaini's core brand, Winona, has been a major revenue driver, contributing approximately 97% of total revenue in 2022, which decreased to around 86% in 2024, indicating a heavy reliance on a single brand [9]. - Other beauty brands, such as Proya and Marubi, are also increasing their capital investments to seek growth, highlighting a trend among leading beauty companies to diversify and enhance their market positions [10][11].

Core Viewpoint - The stock of Betaini has experienced fluctuations, with a recent decline of 2.12%, reflecting a total market value of 19.55 billion yuan and a year-to-date increase of 9.66% [1] Financial Performance - For the first half of 2025, Betaini reported a revenue of 2.372 billion yuan, a year-on-year decrease of 15.43%, and a net profit attributable to shareholders of 247 million yuan, down 49.01% compared to the previous year [2] - Since its A-share listing, Betaini has distributed a total of 1.289 billion yuan in dividends, with 844 million yuan distributed over the past three years [3] Shareholder Information - As of August 29, 2025, the number of shareholders for Betaini increased to 37,700, with an average of 11,237 circulating shares per person, a slight decrease of 0.53% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and E Fund's ChiNext ETF, with significant increases in their holdings [3]

Core Insights - Yunnan Betaini Biotechnology Group Co., Ltd. announced an investment of 50 million yuan as a limited partner in the establishment of a 1 billion yuan Wuxi Jinyu Maowu Medical Health Industry Investment Partnership [1] - The fund will focus on investment areas including consumer healthcare, wellness, medical aesthetics, special medical and functional foods, pharmaceuticals, medical devices, and AI pharmaceuticals [1][3] - Betaini's investment strategy is aimed at addressing the slowdown in its main business growth, as evidenced by a projected decline in net profit of around 30% for 2023 and 2024 [5][6] Investment Activities - Since 2022, Betaini has participated in multiple industry investment funds, including a 100 million yuan investment in Hangzhou Sequoia Shengheng Equity Investment Partnership in June 2022 and another 100 million yuan in Nanjing Jianye Sanzheng Equity Investment Partnership in April 2023 [3] - The company has made at least 12 investment events covering various fields such as pharmaceuticals, medical devices, and skincare since 2022 [3] Financial Performance - As of June 30, 2023, Betaini reported a decline in both revenue and net profit, with total revenue of 236.77 million yuan and a net profit of 44.06 million yuan, reflecting a negative growth trend [6] - The company's net profit is projected to decline by approximately 30% in both 2023 and 2024, indicating challenges in maintaining profitability [5][6] Industry Context - The beauty and cosmetics industry is increasingly engaging in investment activities, with major companies like Proya, Marubi, and Water Sheep also establishing investment funds and making substantial investments [6] - The competitive landscape in the beauty industry is evolving, with a focus on building an ecosystem for sustainable growth through capital strategies [7]

10月13日，贝泰妮公告称，为把握战略合作机会，公司拟作为有限合伙人，与无锡金鹫投资合伙企业（有限合伙）、江苏无锡 生物医药产业专项母基金（有限合伙）、江阴高新区金融投资有限公司、江阴市金融投资有限公司等多方共同出资设立无锡金 雨茂物医疗健康产业投资合伙企业（有限合伙）（简称"金雨基金"）。 该基金计划总规模10亿元，主要投资方向包括消费医疗及国民健康质量提升（含康养、医美、特医及功能食品等）、药物（含 合成生物学、创新药等）、医疗器械、医疗支持性产业、AI制药等领域。其中，贝泰妮拟认缴5000万元，将持有该基金5%份 额。 21世纪经济报道记者朱艺艺 报道 "功效护肤第一股"贝泰妮（300957）（300957.SZ），正加码资本领域布局。 另据21世纪经济报道记者梳理，近年来，贝泰妮先后参投了"红杉基金"、"三正基金"、"金皋基金"等多个基金，将触角延伸至资 本端，在美妆主业之外挖掘更多的业务增量。 三年参投基金2.8亿元 | 投资时间 | 基金名称 | 拟投资规模 | | --- | --- | --- | | 2022 年 6 月 | 杭州红杉晟恒股权投资合伙企业(有限 | 1 亿元 | | | 合伙 ...

Core Viewpoint - Betaini, known as the "first stock in functional skincare," is intensifying its capital market strategy by establishing a new investment fund focused on healthcare and medical industries [1][3]. Investment Fund Overview - Betaini plans to invest as a limited partner in the Wuxi Jinyu Maowu Medical Health Industry Investment Partnership, with a total fund size of 1 billion yuan, focusing on consumer healthcare, pharmaceuticals, medical devices, and AI in drug development [1][3]. - The company will contribute 50 million yuan, acquiring a 5% stake in the fund, which has a 10-year partnership duration [2][3]. Historical Investment Activities - Over the past three years, Betaini has invested approximately 280 million yuan across various funds, including Sequoia Fund and San Zheng Fund, indicating a strategic shift towards capital investments beyond its core beauty business [2][4]. - Specific investments include 100 million yuan in Sequoia Fund in June 2022, 100 million yuan in San Zheng Fund in April 2023, and 30 million yuan in Jiangsu Jinguo New Materials Fund in October 2023 [2][4]. Financial Performance and Strategic Concerns - Betaini's revenue growth has been declining, with revenues of 4.022 billion yuan in 2021, 5.014 billion yuan in 2022, 5.522 billion yuan in 2023, and 5.736 billion yuan in 2024, showing a decreasing growth rate from 52.57% to 3.87% [6]. - The company's net profit has also decreased significantly, from 8.63 billion yuan in 2021 to 5.03 billion yuan in 2024, reflecting a trend of increasing revenue but declining profitability [6]. Brand Diversification Efforts - To mitigate reliance on its core brand Winona, which accounted for approximately 86% of total revenue in 2024, Betaini is expanding its brand portfolio by acquiring stakes in other brands and developing a multi-brand strategy [6][7]. - The company has invested 536 million yuan to acquire a 51% stake in Yuejiang (Guangzhou) Investment Co., aiming to integrate brands like Za and Pure&Mild into its offerings [6]. Industry Trends - Other major beauty brands, such as Proya and Marubi, are also increasing their capital investments to seek growth opportunities amid slowing sales, indicating a broader trend in the beauty industry towards capital market engagement [7][8].

Group 1 - The cosmetics sector experienced a significant increase of 3.35% on October 15, with Shuiyang Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] - Major stocks in the cosmetics sector showed notable price increases, with Shuiyang Co., Ltd. rising by 8.45% to a closing price of 25.03 [1] Group 2 - The net inflow of main funds in the cosmetics sector was 219 million yuan, while retail investors saw a net outflow of 222 million yuan [1] - Shanghai Jahwa's main fund net inflow was 85.02 million yuan, with a retail net outflow of 66.90 million yuan [2] - Shuiyang Co., Ltd. had a main fund net inflow of 46.76 million yuan, but a retail net outflow of 69.20 million yuan [2]

Core Insights - The cosmetics sector experienced a slight increase of 0.31% on October 14, with Shanghai Jahwa leading the gains [1] - The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1] Company Performance - Shanghai Jahwa (600315) closed at 26.59, up 5.10%, with a trading volume of 102,700 shares and a transaction value of 270 million yuan [1] - Lafang (603630) closed at 24.65, up 4.05%, with a trading volume of 90,200 shares and a transaction value of 221 million yuan [1] - Qingdao Kingway (002094) closed at 7.97, up 1.92%, with a trading volume of 413,400 shares and a transaction value of 329 million yuan [1] - Other notable performers include Bawei (920123) at 17.83 (+1.54%) and Jinsong New Materials (300849) at 13.53 (+0.97%) [1] Fund Flow Analysis - The cosmetics sector saw a net outflow of 13.28 million yuan from institutional investors, while retail investors experienced a net outflow of 46.69 million yuan [2] - Conversely, speculative funds recorded a net inflow of 59.98 million yuan [2] Individual Stock Fund Flow - Shanghai Jahwa had a net inflow of 29.86 million yuan from institutional investors, while retail investors saw a net outflow of 24.90 million yuan [3] - Lafang recorded a net inflow of 21.89 million yuan from institutional investors, with retail investors experiencing a net outflow of 21.61 million yuan [3] - Qingdao Kingway had a net inflow of 16.80 million yuan from institutional investors, while retail investors saw a net outflow of 18.67 million yuan [3]

Core Viewpoint - Betta Pharmaceuticals (300957.SZ) aims to enhance its comprehensive competitiveness and profitability by becoming a limited partner in a new investment fund focused on the healthcare sector [1] Group 1: Investment Details - The company will invest 50 million yuan as a limited partner in the Wuxi Jinyu Maowu Medical Health Industry Investment Partnership, holding a 5% share in the fund [1] - The fund is established in collaboration with several partners, including Wuxi Jinjiao Investment Partnership and Jiangsu Wuxi Biomedical Industry Special Mother Fund [1] Group 2: Investment Focus - The partnership will primarily invest in areas such as consumer healthcare, quality improvement of national health, pharmaceuticals (including synthetic biology and innovative drugs), medical devices, supportive medical industries, and AI-driven pharmaceuticals [1]

Core Viewpoint - Betta Pharmaceuticals (300957.SZ) aims to enhance its comprehensive competitiveness and profitability by becoming a limited partner in a new investment fund focused on the healthcare industry [1] Group 1: Investment Details - The company will invest 50 million yuan as a limited partner in the Wuxi Jinyu Maowu Medical Health Industry Investment Partnership, holding a 5% share in the fund [1] - The fund is established in collaboration with several partners, including Wuxi Jinjiao Investment Partnership and Jiangsu Wuxi Biomedical Industry Special Mother Fund [1] Group 2: Investment Focus - The partnership will primarily invest in sectors such as consumer healthcare, quality improvement of national health, pharmaceuticals (including synthetic biology and innovative drugs), medical devices, supportive medical industries, and AI-driven pharmaceuticals [1]

北京商报讯(记者张君花)10月13日，贝泰妮（300957）发布公告称，公司于近日签署《无锡金雨茂物医 疗健康产业投资合伙企业(有限合伙)合伙协议》。金雨基金由金雨茂物投资管理股份有限公司担任基金 管理人。其中，公司作为金雨基金的有限合伙人之一，使用自有资金认缴出资5000万元，本次投资完成 后公司将持有金雨基金5%的合伙份额。该合伙企业主要投资于消费医疗及国民健康质量提升(含康养、 医美、特医及功能食品等)、药物(含合成生物学、创新药等)、医疗器械、医疗支持性产业、AI制药等 领域。 ...